181 related articles for article (PubMed ID: 2219316)
1. The interaction of IL-2 and IL-4 with the effects of deoxyspergualin.
Kerr PG; Atkins RC
Transplant Proc; 1990 Oct; 22(5):2121-2. PubMed ID: 2219316
[No Abstract] [Full Text] [Related]
2. In vitro immunosuppressive effect of deoxymethylspergualin.
Jiang H; Takahara S; Takano Y; Machida M; Iwasaki A; Kokado Y; Kameoka H; Moutabarrik A; Ishibashi M; Sonoda T
Transplant Proc; 1990 Aug; 22(4):1633-7. PubMed ID: 2143857
[No Abstract] [Full Text] [Related]
3. Effects of 15-deoxyspergualin on the induction of cytotoxic T lymphocytes and bone marrow suppression.
Nishimura K; Tokunaga T
Transplant Proc; 1989 Feb; 21(1 Pt 1):1104-7. PubMed ID: 2784883
[No Abstract] [Full Text] [Related]
4. Immunosuppressive mechanisms of deoxymethylspergualin and FK 506 on in vitro cytotoxic T lymphocytes.
Nakata S; Shirakura R; Ito T; Fukuzawa M; Miyagawa S; Yamamoto S; Nozaki T; Matsumiya G; Izutani H; Matsuda H
Transplant Proc; 1994 Aug; 26(4):1930-2. PubMed ID: 7520613
[No Abstract] [Full Text] [Related]
5. 15-Deoxyspergualin produces inhibition of lymphokine-activated killer cell activity.
Thomas F; Matthews C; Pittman K; Thomas J
Transplant Proc; 1992 Apr; 24(2):712-3. PubMed ID: 1566494
[No Abstract] [Full Text] [Related]
6. Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes.
Mehrotra PT; Wu D; Crim JA; Mostowski HS; Siegel JP
J Immunol; 1993 Sep; 151(5):2444-52. PubMed ID: 8103066
[TBL] [Abstract][Full Text] [Related]
7. Ergot alkaloid-induced cell proliferation, cytotoxicity, and lymphokine production.
Fiserová A; Trinchieri G; Chan S; Bezouska K; Flieger M; Pospisil M
Adv Exp Med Biol; 1995; 371A():163-6. PubMed ID: 8525898
[No Abstract] [Full Text] [Related]
8. Inhibition of CTL induction by rapamycin: IL-2 rescues granzyme B and perforin expression but only partially restores cytotoxic activity.
Makrigiannis AP; Hoskin DW
J Immunol; 1997 Nov; 159(10):4700-7. PubMed ID: 9366393
[TBL] [Abstract][Full Text] [Related]
9. Deoxyspergualin inhibits cytotoxic T lymphocytes but not NK or LAK cells.
Kerr PG; Atkins RC
Immunol Cell Biol; 1991 Jun; 69 ( Pt 3)():177-83. PubMed ID: 1835710
[TBL] [Abstract][Full Text] [Related]
10. CTL generation in the presence of IL-4 is inhibited by free p40: evidence for early and late IL-12 function.
Abdi K; Herrmann SH
J Immunol; 1997 Oct; 159(7):3148-55. PubMed ID: 9317112
[TBL] [Abstract][Full Text] [Related]
11. Cytokine combinations for induction of antigen-specific cytolytic T lymphocytes from peripheral blood lymphocytes.
Tsujitani S; Nakashima M; Watanabe T; Kaibara N; Koprowski H; Steplewski Z
Anticancer Res; 1995; 15(3):655-60. PubMed ID: 7645938
[TBL] [Abstract][Full Text] [Related]
12. Restoration of cytotoxic T lymphocyte function in malignant pleural effusion: interleukin-15 vs. interleukin-2.
Chen YM; Ting CC; Peng JW; Yang WK; Yang KY; Tsai CM; Perng RP
J Interferon Cytokine Res; 2000 Jan; 20(1):31-9. PubMed ID: 10670650
[TBL] [Abstract][Full Text] [Related]
13. In vitro immunosuppressive properties of spergualins to murine T cell response.
Fujii H; Takada T; Nemoto K; Abe F; Fujii A; Takeuchi T
J Antibiot (Tokyo); 1989 May; 42(5):788-94. PubMed ID: 2524464
[TBL] [Abstract][Full Text] [Related]
14. The effects of deoxyspergualin on lymphocytes and monocytes in vivo and in vitro.
Kerr PG; Atkins RC
Transplantation; 1989 Dec; 48(6):1048-52. PubMed ID: 2531949
[TBL] [Abstract][Full Text] [Related]
15. Reactivity of peripheral blood lymphocytes to recombinant interleukin-2 in kidney transplant recipients.
Koda N; Oda T; Yokoyama M; Matsumoto A; Takeuchi M
Transplant Proc; 1990 Oct; 22(5):2373-5. PubMed ID: 2219405
[No Abstract] [Full Text] [Related]
16. 15-Deoxyspergualin, a novel immunosuppressive drug: studies of the mechanism of action.
Tepper MA; Nadler S; Mazzucco C; Singh C; Kelley SL
Ann N Y Acad Sci; 1993 Jun; 685():136-47. PubMed ID: 8363218
[No Abstract] [Full Text] [Related]
17. Comparison between crude interleukin-2 and recombinant interleukin-2 in maintaining killing activity of cultured lymphocytes.
Nakanishi M; Kan N; Okino T; Satoh K; Mise K; Teramura Y; Yamasaki S; Ohgaki K; Tobe T
Biotherapy; 1990; 2(1):21-32. PubMed ID: 2119201
[TBL] [Abstract][Full Text] [Related]
18. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.
Owen-Schaub LB; Gutterman JU; Grimm EA
Cancer Res; 1988 Feb; 48(4):788-92. PubMed ID: 3257408
[TBL] [Abstract][Full Text] [Related]
19. Combined immunosuppressive effect of FK 506 and other immunosuppressive agents on PHA- and CD3-stimulated human lymphocyte proliferation in vitro.
Jiang H; Suguo H; Takahara S; Takano Y; Li D; Kameoka H; Moutabarrik A; Kokado Y; Ishibashi M; Okuyama A
Transplant Proc; 1991 Dec; 23(6):2933-6. PubMed ID: 1721317
[No Abstract] [Full Text] [Related]
20. Effects of serum immunosuppressive factors on antitumor cytotoxicity of interleukin 2-induced lymphocytes.
Sugiyama Y; Sakata K; Saji S; Takao H; Hamuro J
J Surg Oncol; 1987 Aug; 35(4):223-9. PubMed ID: 3497306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
